Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Multidose, Open-Label Study to Evaluate the Safety and Immunomodulatory Effects of SCV-07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Genotype 1 Chronic Hepatitis C Who Have Relapsed After a Response to a Course of at Least 44 Weeks Treatment With Pegylated Interferon and Ribavirin

NCT00968357 is registered in ClinicalTrials.gov with SciClone Pharmaceuticals as lead sponsor.

NCT NCT00968357
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00968357 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Multidose, Open-Label Study to Evaluate the Safety and Immunomodulatory Effects of SCV-07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Genotype 1 Chronic Hepatitis C Who Have Relapsed After a Response to a Course of at Least 44 Weeks Treatment With Pegylated Interferon and Ribavirin
Lead sponsor
SciClone Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
January 31, 2011
Enrollment
40 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c